Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications [0.03%]
错配修复蛋白表达缺失和微卫星不稳定性在上尿路尿路上皮癌中的发生及其临床病理意义
Björn Schneider,Änne Glass,Sandra Jagdmann et al.
Björn Schneider et al.
Background: Upper tract urothelial carcinoma (UTUC) may arise in the setting of hereditary non-polyposis colorectal cancer (Lynch syndrome [LS]) or sporadically. Variable frequencies of microsatellite instability (MSI) we...
Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma [0.03%]
局部晚期、淋巴结阳性、无转移的阴茎鳞状细胞癌的根治性化学放射治疗
Kyra McComas,Neeraj Agarwal,Glen Bowen et al.
Kyra McComas et al.
Introduction: Locally advanced penile cancer is rare, with few reported studies on the therapeutic role of chemoradiotherapy. We sought to characterize the efficacy and toxicity of definitive chemoradiotherapy for locally...
Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer [0.03%]
量化早期根治性膀胱切除术对组织学确诊的T1期非肌层浸润性膀胱癌患者的总生存益处
Karl H Tully,Florian Roghmann,Joachim Noldus et al.
Karl H Tully et al.
Introduction: The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment o...
Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy [0.03%]
局部高危和很高危前列腺癌患者手术及/或综合放疗后的转移、生存率及生活质量
Jonathan D Tward,Brock O&#x;Neil,Ken Boucher et al.
Jonathan D Tward et al.
Purpose: To compare metastasis-free survival, overall survival, and patient-reported quality of life (QOL) of men with National Comprehensive Cancer Network high or very high risk prostate cancer after definitive surgery ...
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment [0.03%]
关于塞韦特若那（INO-464）治疗恩杂鲁胺治疗后转移性去势抵抗性前列腺癌的II期研究
Ravi A Madan,Keith T Schmidt,Fatima Karzai et al.
Ravi A Madan et al.
Background: Seviteronel was being developed by Innocrin Pharmaceuticals as a selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) inhibitor and androgen receptor antagonist with activity against prostate cancer cells...
Corrigendum [0.03%]
勘误表
Published Erratum
Clinical genitourinary cancer. 2020 Aug;18(4):e416-e417. DOI:10.1016/j.clgc.2020.03.014 2020
Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer [0.03%]
评估ERα激动剂GTX-758/GIREDEPO在去势抵抗性前列腺癌男性患者中疗效的2期临床试验
Evan Y Yu,Michael L Hancock,William Aronson et al.
Evan Y Yu et al.
Introduction: Novel estrogen therapy has the potential to be efficacious, with a favorable adverse event profile, in castration-resistant prostate cancer (CRPC). We performed a phase 2 trial to assess the ability of GTx-7...
First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis [0.03%]
免疫治疗时代的转移性肾细胞癌一线治疗：系统评价和网络 meta 分析
Fernando Sabino M Monteiro,Andrey Soares,Márcio Debiasi et al.
Fernando Sabino M Monteiro et al.
Combination treatments with immuno-oncology (IO) agents and IO agents plus a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) have been approved for first-line treatment of patients with metastatic renal cel...
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer [0.03%]
卡博替尼治疗未经基因检测的去势抵抗性前列腺癌骨转移疗效及药效学研究
David C Smith,Stephanie Daignault-Newton,Petros Grivas et al.
David C Smith et al.
Background: Cabozantinib is active in advanced prostate cancer with improvement on bone scans in men on phase II trials. This trial evaluated the efficacy and changes in bone lesions in men with metastatic castration-resi...
The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy [0.03%]
仑伐替尼联合依维莫司治疗一线靶向或免疫治疗原发耐药的晚期肾细胞癌患者的疗效研究
Lana Hamieh,Rachel L Beck,Valerie H Le et al.
Lana Hamieh et al.
Background: Patients with primary refractory metastatic renal cell carcinoma (mRCC) have a dismal prognosis and poor response to subsequent treatments. While there are several approved second-line therapies, it remains cr...